Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CNS

- PMLiVE

Roche, Regeneron partner on COVID-19 antibody cocktail

Collaboration agreement will bolster global development and manufacturing capabilities

- PMLiVE

Merck enters agreement with Hanmi for investigational NASH drug

Licensing agreement includes $10m upfront payment

- PMLiVE

Genfit scraps phase 3 trial of experimental NASH drug

Drug failed to meet primary endpoint in interim analysis

- PMLiVE

Regeneron’s COVID-19 antibody cocktail enters phase 3 trial

Drug will be evaluated in preventative trial testing uninfected participants

Sanofi reception

Sanofi doses first patient in global Kevzara COVID-19 trial

Sanofi is leading trials outside the US while Regeneron is leading US trials

- PMLiVE

Sanofi, Regeneron launch trials of arthritis drug Kevzara for COVID-19

The interleukin-6 inhibitor will be evaluated in critically ill patients

- PMLiVE

Zydus Cadila scores first ever NASH approval, in India

Drug has already been approved for diabetes related conditions

- PMLiVE

Alnylam scores EU approval for RNAi drug Givlaari

Company says it will work towards value-based agreements for the drug

- PMLiVE

FDA delays decision on Intercept’s NASH drug by three months

Action date pushed back to 26 June

- PMLiVE

Keeping up the fight against HIV and using the lessons to tackle other threats

Danny Buckland interviews Gilead’s Mike Elliott

- PMLiVE

Boehringer bolsters NASH pipeline with Enleofen link-up

Agrees to pay up to €1bn for each new marketed product

- PMLiVE

Northsea Therapeutics raises $40m to develop fish oil NASH drug

Looking for mid-stage trial success in field littered with failures

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links